Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L4	398	T ADJ "1249"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L5	3	(T ADJ "1249") same Peg\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L6	7	(T ADJ "1249") same Glycol\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L7	0	(gp41 same HIV same Glycol\$) same pegyl\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L8	17	gp41 same HIV same Glycol\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L9 ·	5791	Pegyl\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L10	702	Pegyl\$ SAME linker	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L11	990	Pegyl\$ SAME Length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L12	63	(Pegyl\$ SAME linker) and (Pegyl\$ SAME Length)	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L13	2	(("5464933") or ("5656480")).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2005/12/02 15:35
L14	8940	Glycol same peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L15	1500	(Glycol same peptide) same conjugat\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L16	1500	(Glycol same peptide) and ((Glycol same peptide) same conjugat\$)	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L17	29	glycol ADJ length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L18	1354	PEG same Spacer	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35

		r				
L19	183	(PEG same Spacer) same length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L20	23	Polyethylene same glycol same protein same spacer same length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L21	4	(Polyethylene same glycol same protein same spacer same length) same peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L22	73	Glycol same length same increase same half adj life	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:35
L23	1	("4,261,973").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2005/12/02 15:35
L24	1	("6348568").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2005/12/02 15:36
L25	134460	Insulin SMAE PEG	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L26	555	Insulin SAME PEG	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L27	0	Insulin SAME PEG SAME conmjugated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L28	102	Insulin SAME PEG SAME conjugated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L29 _.	2	HIV SAME PEG SAME conjugated SAME Peptide	US-PGPUB; USPAT; EPO; JPO	OR .	ON	2005/12/02 15:36
L30	1	("6469136").PN.	US-PĢPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2005/12/02 15:36
L31	5769	Pegylation or Pegylated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L32	694	(Pegylation or Pegylated) same linker	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L33	2249	(Pegylation or Pegylated) same attach\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36

124	100	(D 1-12 D 1-11)	HC BCBHB	00	-	2005/42/02 45 04
L34	182	(Pegylation or Pegylated) same attach	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L35	143	(Pegylation or Pegylated) same coupl\$ same aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L36	79	PEG-aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L37	3	(T ADJ "1249") same Peg\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L38	398	T ADJ "1249"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L39	4045	t adj "20"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L40	991	T-20	US-PGPUB; USPAT; EPO; JPO	OR	ON .	2005/12/02 15:36
L41	6	T-20 same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L42	2	T-20 same peptide same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L43	1	("6469136").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2005/12/02 15:36
L44	2	(T adj "20") same peptide same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L45	4	gp41 same peptide same peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L46	75	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L47	400838	L46 same polyethylene glycol	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L48	13	L46 same polyethylene same glycol	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L49	1	("6348568").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2005/12/02 15:36


F	1001					
L50	1201	Peg same aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L51	52	Polyethylene adj glycol adj aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L52	1	("6469136").PN.	US-PGPUB; USPAT; EPO; JPO	OR .	OFF	2005/12/02 15:36
L53	1	("5,252,714").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2005/12/02 15:36
L54	75	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON .	2005/12/02 15:36
L55	0	PEG adj YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L56	0	Peg-YTSLIHSLIEESQNQQEKNEQEL LELDKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L57	1	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF same peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
L58	13	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF same polyethylene	US-PGPUB; USPAT; EPO; JPO	OR	ON	2005/12/02 15:36
S1	279	T ADJ "1249"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/06 14:15
S2	2	(T ADJ "1249") same Peg\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/18 16:01
S3	5	(T ADJ "1249") same Glycol\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/18 16:17
S4	0	(gp41 same HIV same Glycol\$) same pegyl\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/18 16:18
S5	11	gp41 same HIV same Glycol\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/18 16:18
S6	4052	Pegyl\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 10:42
S7	483	Pegyl\$ SAME linker	US-PGPUB; USPAT; EPO; JPO	OR .	ON	2004/10/19 10:43

	,		· · · · · · · · · · · · · · · · · · ·		1	
S8	790	Pegyl\$ SAME Length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 10:43
S9	. 35	(Pegyl\$ SAME linker) and (Pegyl\$ SAME Length)	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 10:53
S10	2	(("5464933") or ("5656480")).PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR .	OFF	2004/10/19 11:16
S11	6722	Glycol same peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:17
S12	1062	(Glycol same peptide) same conjugat\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:17
S13	1062	(Glycol same peptide) and ((Glycol same peptide) same conjugat\$)	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:17
S14	25	glycol ADJ length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:38
S15	1101	PEG same Spacer	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:38
S16 ⁻	147	(PEG same Spacer) same length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:39
S17	17	Polyethylene same glycol same protein same spacer same length	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:42
S18	. 1	(Polyethylene same glycol same protein same spacer same length) same peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:46
S19	42	Glycol same length same increase same half adj life	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 11:52
S20		("4,261,973").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2004/10/19 11:54
S21	1	("6348568").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2004/10/19 14:52
S22	112421	Insulin SMAE PEG	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 14:52

S23	408	Insulin SAME PEG	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 14:52
S24	0	Insulin SAME PEG SAME conmjugated	US-PGPUB; USPAT; EPO; JPO	OR	ON .	2004/10/19 14:52
S25	83	Insulin SAME PEG SAME conjugated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 15:07
S26	2	HIV SAME PEG SAME conjugated SAME Peptide	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/10/19 15:07
S27	. 1	("6469136").PN.	US-PGPUB; USPAT; USOCR; EPO; JPO	OR	OFF	2004/10/19 16:07
S28	4100	Pegylation or Pegylated	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 10:54
S29	483	(Pegylation or Pegylated) same linker	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 10:54
S30	1575	(Pegylation or Pegylated) same attach\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 10:55
S31	134	(Pegylation or Pegylated) same attach	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 11:29
S32	104	(Pegylation or Pegylated) same coupl\$ same aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 12:57
S33	54	PEG-aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/11/08 12:57
S34	2	(T ADJ "1249") same Peg\$	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 14:31
S35	293	T ADJ "1249"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 14:26
S36	3407	t adj "20"	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 14:31
S37	780	Т-20	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 14:31
S38	5	T-20 same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 15:07

S39	1	T-20 same peptide same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 15:38
S40	1	("6469136").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2004/12/02 15:34
S41	1	(T adj "20") same peptide same Peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 15:39
S42	4	gp41 same peptide same peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 15:39
S43	57	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 17:29
544	362071	S43 same polyethylene glycol	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 17:30
S45	13	S43 same polyethylene same glycol	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/02 17:36
S46	1	("6348568").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2004/12/02 17:36
S47	902	Peg same aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/06 14:16
S49	45	Polyethylene adj glycol adj aldehyde	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/06 15:08
S50	1	("6469136").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2004/12/06 16:07
S51	1	("5,252,714").PN.	US-PGPUB; USPAT; EPO; JPO	OR	OFF	2004/12/06 16:07
S52	57	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:21
S53	0	PEG adj YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:21
S54	0	Peg-YTSLIHSLIEESQNQQEKNEQEL LELDKWASLWNWF	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:21
S55	1	YTSLIHSLIEESQNQQEKNEQELLEL DKWASLWNWF same peg	US-PGPUB; USPAT; EPO; JPO	OR	ON	2004/12/07 15:24

S56	1	3	YTSLIHSLIEESQNQQEKNEQELLEL	US-PGPUB;	OR	ON	2004/12/07 15:24
		١	DKWASLWNWF same polyethylene	USPAT;			
				EPO; JPO			



```
L39 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
              251562-00-2 REGISTRY
RN
              Entered STN: 22 Dec 1999
ED
              L-Phenylalanina mide, \ N-acetyl-L-tryptophyl-L-glutaminyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-\alpha-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-gluta
              L-tryptophyl-L-\alpha-glutamyl-L-glutaminyl-L-lysyl-L-isoleucyl-L-
               threonyl-L-alanyl-L-leucyl-L-leucyl-L-a-glutamyl-L-glutaminyl-L-
               alanyl-L-glutaminyl-L-isoleucyl-L-glutaminyl-L-glutaminyl-L-\alpha-
              glutamyl-L-lysyl-L-asparaginyl-L-\alpha-glutamyl-L-tyrosyl-L-\alpha-
              glutamyl-L-leucyl-L-glutaminyl-L-lysyl-L-leucyl-L-α-aspartyl-L-lysyl-
               L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-tryptophyl-L-α-glutamyl-L-
               tryptophyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
              1: PN: WO9959615 PAGE: 68 claimed protein
'CN
               T 1249
CN
CN
               Tifuvirtide
               PROTEIN SEOUENCE
FS
               C235 H341 N57 O67
MF
CI
              MAN
               CA
SR
               STN Files: ADISINSIGHT, BIOSIS, BIOTECHNO, CA, CAPLUS, EMBASE,
LC
                     IMSRESEARCH, PHAR, PROUSDDR, TOXCENTER, USAN, USPAT7, USPATFULL
 **RELATED SEQUENCES AVAILABLE WITH SEQLINK**
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 **PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
                                          44 REFERENCES IN FILE CA (1907 TO DATE)
                                            4 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
                                          44 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

=>

```
L40 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN
RN
           159519-65-0 REGISTRY
ED
           Entered STN: 13 Dec 1994
           L-Phenylalaninamide, N-acetyl-L-tyrosyl-L-threonyl-L-seryl-L-leucyl-L-
CN
           isoleucyl-L-histidyl-L-seryl-L-leucyl-L-isoleucyl-L-\alpha-glutamyl-L-isoleucyl-L-\alpha-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-a-glutamyl-L-isoleucyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-A-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-A-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-A-a-glutamyl-L-a-glutamyl-L-a-glutamyl-L-a-glutamyl-A-glutamyl-L-a-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-A-glutamyl-
           \alpha-glutamyl-L-seryl-L-glutaminyl-L-asparaginyl-L-glutaminyl-L-
           glutaminyl-L-\alpha-glutamyl-L-lysyl-L-asparaginyl-L-\alpha-glutamyl-L-
           glutaminyl-L-\alpha-glutamyl-L-leucyl-L-leucyl-L-\alpha-glutamyl-L-
           leucyl-L-\alpha-aspartyl-L-lysyl-L-tryptophyl-L-alanyl-L-seryl-L-leucyl-L-
           tryptophyl-L-asparaginyl-L-tryptophyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
           1: PN: US20020146415 PAGE: 10 claimed protein
ČN
           1: PN: US20030044411 PAGE: 10 claimed protein
CN
           1: PN: WO0155439 SEQID: 1 claimed protein
CN
           1: PN: WO0224149 PAGE: 24 claimed protein
CN
           414: PN: WOO164013 FIGURE: 24 claimed protein
CN
           636: PN: WO0151673 FIGURE: 54 claimed protein
CN
           6: PN: WO2004091542 SEQID: 7 claimed protein
CN
CN
           DP 178
           Enfuvirtide
CN
CN
           Fuzeon
           GP 41-127-162AA
CN
           Pentafuside
CN
           T 20
CN
           T 20 (peptide)
CN
           PROTEIN SEQUENCE
 FS
           262434-79-7
DR
           C204 H301 N51 O64
MF
CI
           MAN
SR
                                        ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA,
T.C.
           STN Files:
                CAPLUS, CHEMCATS, CIN, DIOGENES, EMBASE, IMSDRUGNEWS, IMSPATENTS,
                IMSRESEARCH, IPA, MRCK*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*,
                TOXCENTER, USAN, USPAT2, USPATFULL
                     (*File contains numerically searchable property data)
 **RELATED SEQUENCES AVAILABLE WITH SEQLINK**
 *** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 *** USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE ***
 **PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**
                              239 REFERENCES IN FILE CA (1907 TO DATE)
                           10 REFERENCES TO NON-SPECIFIC DERIVATIVES II
243 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Poly(a)kylewe glycol)
                                10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
```

> d his ful

L1

L7

L9

(FILE 'HOME' ENTERED AT 15:03:48 ON 02 DEC 2005)

FILE 'REGISTRY' ENTERED AT 15:04:00 ON 02 DEC 2005

STRUCTURE UPLOADED

L2 9 SEA SSS SAM L1

L3 72 SEA SSS FUL L1

FILE 'HCAPLUS' ENTERED AT 15:05:18 ON 02 DEC 2005

L4 31 SEA PLU=ON L3

L5 6 SEA PLU=ON L4 AND (PEG OR (POLYETHYLENE (W) GLYCOL) OR (POLY

(W) ETHYLENE (W) GLYCOL))
D L5 1-6 IBIB HITSTR

D OUE STA

FILE 'USPATFULL, USPAT2' ENTERED AT 15:10:37 ON 02 DEC 2005

L6 16 SEA PLU=ON L3

9 SEA PLU=ON L6 NOT L5

FILE 'CASREACT' ENTERED AT 15:10:57 ON 02 DEC 2005

L8 3 SEA PLU=ON L3

2 SEA PLU=ON L8 NOT L5

D L9 1-2 IBIB RX

D L9 1-2 SBIB

FILE 'CASREACT' ENTERED AT 15:13:10 ON 02 DEC 2005

D L9 1-2 SBIB

FILE 'USPATFULL, USPAT2' ENTERED AT 15:13:39 ON 02 DEC 2005

D L7 1-9 CBIB

D L7 1-9 IBIB HITSTR

FILE HOME

FILE REGISTRY

STRUCTURE FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8 DICTIONARY FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *

* the IDE default display format and the ED field has been added, *

* effective March 20, 2005. A new display format, IDERL, is now *

* available and contains the CA role and document type information. *

Structure search iteration limits have been increased. See ${\tt HELP}$ SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Dec 2005 VOL 143 ISS 24 FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Dec 2005 (20051201/PD) FILE LAST UPDATED: 1 Dec 2005 (20051201/ED) CA INDEXING IS CURRENT THROUGH 1 Dec 2005 (20051201/UPCA) ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Dec 2005 (20051201/PD) REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 1 Dec 2005 (20051201/PD)
FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)
CA INDEXING IS CURRENT THROUGH 1 Dec 2005 (20051201/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Dec 2005 (20051201/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005

FILE CASREACT

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1840 - 27 Nov 2005 VOL 143 ISS 22

New CAS Information Use Policies, enter HELP USAGETERMS for details.

Some CASREACT records are derived from the ZIC/VINITI database (1974-1991) provided by InfoChem, INPI data prior to 1986, and Biotransformations database compiled under the direction of Professor Dr. Klaus Kieslich.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Welcome to STN International! Enter x:x

LOGINID:SSSPTATSH1654

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * *	* *	* *	* *	* Welcome to STN International * * * * * * * * *
NEWS	1			Web Page URLs for STN Seminar Schedule - N. America
NEWS	_			"Ask CAS" for self-help around the clock
NEWS	3	SEP	09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4			MATHDI removed from STN
NEWS	5	OCT	04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT	13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT	17	
				of CAplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT	27	Free KWIC format extended in full-text databases
NEWS	9	OCT	27	DIOGENES content streamlined
NEWS	10	OCT	27	EPFULL enhanced with additional content
NEWS	11	NOV	14	CA/CAplus - Expanded coverage of German academic research
NEWS				REGISTRY/ZREGISTRY on STN(R) enhanced with experimental
				spectral property data
NEWS	EXP	RESS		CEMBER 02 CURRENT VERSION FOR WINDOWS IS V8.01,
				RRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
			ANI	CURRENT DISCOVER FILE IS DATED 02 DECEMBER 2005.
				.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
			htt	cp://download.cas.org/express/v8.0-Discover/
NEWS				N Operating Hours Plus Help Desk Availability
NEWS				neral Internet Information
NEWS				Lcome Banner and News Items
NEWS				rect Dial and Telecommunication Network Access to STN
NEWS	WWW		CAS	S World Wide Web Site (general information)
T 4	AT 177.7	a e 1	3	

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:38:01 ON 02 DEC 2005

=> file registry COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 14:38:16 ON 02 DEC 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8 DICTIONARY FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The CA roles and document type information have been removed from *

* the IDE default display format and the ED field has been added, *

* effective March 20, 2005. A new display format, IDERL, is now *

* available and contains the CA role and document type information. *

* *

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10625103Claim2and 3.str

L1 STRUCTURE UPLOADED

=> dis

1.1

L1 HAS NO ANSWERS

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full FULL SEARCH INITIATED 14:38:56 FILE 'REGISTRY' FULL SCREEN SEARCH COMPLETED - 204147 TO ITERATE

100.0% PROCESSED 204147 ITERATIONS

SEARCH TIME: 00.00.03

391 SEA SSS FUL L1

=> file hcap uspatful

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 161.76 161.97

FILE 'HCAPLUS' ENTERED AT 14:39:42 ON 02 DEC 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:39:42 ON 02 DEC 2005 CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

=> 12

243 L2 L3

=> L3 and T20

L43 L3 AND T20

=> L3 and T1249

4 L3 AND T1249

=> L4 and L5

L6 2 L4 AND L5

=> d 13 1-3 ibib abs hitstr

ANSWER 1 OF 243 HCAPLUS COPYRIGHT 2005 ACS on STN

2005:1050829 HCAPLUS ACCESSION NUMBER:

143:353334 DOCUMENT NUMBER:

TITLE: PSMA formulations and use thereof for prostate cancer

therapy

INVENTOR(S): Schulke, Norbert; Maddon, Paul J.; Olson, William C.

PSMA Development Company, LLC, USA PATENT ASSIGNEE(S):

U.S. Pat. Appl. Publ., 167 pp., Cont.-in-part of U.S. SOURCE:

Ser. No. 695,667.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005215472	A1	20050929	US 2004-976352	20041027
WO 2003034903	A2	20030501	. WO 2002-US33944	20021023
WO 2003034903	A3	20031030		
WO 2003034903	B1	20040513		•
W: AE, AG,	AL, AM, AT	, AU, AZ,	BA, BB, BG, BR, BY,	BZ, CA, CH, CN,
CO, CR,	CU, CZ, DE	, DK, DM,	DZ, EC, EE, ES, FI	GB, GD, GE, GH,
GM, HR,	HU, ID, IL	, IN, IS,	JP, KE, KG, KP, KR	KZ, LC, LK, LR,
LS, LT,	LU, LV, MA	, MD, MG,	MK, MN, MW, MX, MZ	NO, NZ, OM, PH,
PL, PT,	RO, RU, SD	, SE, SG,	SI, SK, SL, TJ, TM	TN, TR, TT, TZ,
UA, UG,	US, UZ, VN	, YU, ZA,	ZW	
RW: GH, GM,	KE, LS, MW	, MZ, SD,	SL, SZ, TZ, UG, ZM,	ZW, AM, AZ, BY,
			BE, BG, CH, CY, CZ	

391 ANSWERS

```
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,
             CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 2004033229
                          A1
                                 20040219
                                             US 2003-395894
                                                                     20030321
     US 2004161776
                          A1
                                 20040819
                                             US 2003-695667
                                                                     20031027
                                             US 2001-335215P
PRIORITY APPLN. INFO.:
                                                                  Ρ
                                                                     20011023
                                             US 2002-362747P
                                                                  P
                                                                     20020307
                                             US 2002-412618P
                                                                  Ρ
                                                                     20020920
                                             WO 2002-US33944
                                                                  A2 20021023
                                             US 2003-395894
                                                                  A2 20030321
                                             US 2003-695667
                                                                  A2 20031027
```

AB The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compns. and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compns. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.

RN 253119-91-4 HCAPLUS

CN D-Glucose, 2-deoxy-6-0-[2-deoxy-2-[[(3R)-1-oxo-3-[(1oxooctadecyl)oxy]tetradecyl]amino]-3-0-[(3R)-1-oxo-3-[(1oxotetradecyl)oxy]tetradecyl]-4-0-phosphono-β-D-glucopyranosyl]-2-[[(3R)-1-oxo-3-[(1-oxohexadecyl)oxy]tetradecyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

L3 ANSWER 2 OF 243 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:690412 HCAPLUS

DOCUMENT NUMBER: 143:262416

TITLE: Tripeptide Mimetics Inhibit the 20 S Proteasome by

Covalent Bonding to the Active Threonines

AUTHOR(S): Braun, Hannes A.; Umbreen, Sumaira; Groll, Michael;

Kuckelkorn, Ulrike; Mlynarczuk, Izabela; Wigand, Moritz E.; Drung, Ilse; Kloetzel, Peter-Michael;

Schmidt, Boris

CORPORATE SOURCE: Clemens Schoepf-Institute for Organic Chemistry and

Biochemistry, Darmstadt University of Technology,

Darmstadt, D-64287, Germany

SOURCE: Journal of Biological Chemistry (2005), 280(31),

28394-28401

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE: Journal LANGUAGE: English

Proteasomes play an important role in protein turnover in living cells. The inhibition of proteasomes affects cell cycle processes and induces apoptosis. Thus, 20 S proteasomal inhibitors are potential tools for the modulation of neoplastic growth. Based on MG132, a potent but nonspecific 20 S proteasome inhibitor, the authors designed and synthesized 22 compds. and evaluated them for the inhibition of proteasomes. The majority of the synthesized compds. reduced the hydrolysis of LLVY-7-aminomethylcoumarin peptide substrate in cell lysates, some of them drastically. Several compds. displayed inhibitory effects when tested in vitro on isolated 20 ${\mbox{S}}$ proteasomes, with lowest IC50 values of 58 nM (chymotrypsin-like activity), 53 nM (trypsin-like activity), and 100 nM (caspase-like activity). Compds. 16, 21, 22, and 28 affected the chymotrypsin-like activity of the $\beta5$ subunit exclusively, whereas compds. 7 and 8 inhibited the β 2 trypsin-like active site selectively. Compds. 13 and 15 inhibited all three proteolytic activities. Compound 15 was shown to interact with the active site by x-ray crystallog. The potential of these novel inhibitors was assessed by cellular tolerance and biol. response. HeLa cells tolerated up to 1 μM concns. of all substances. Intracellular reduction of proteasomal activity and accumulation of polyubiquitinated proteins were observed for compds. 7, 13, 15, 22, 25, 26, 27, and 28 on HeLa cells. Four of these compds. (7, 15, 26, and 28) induced apoptosis in HeLa cells and thus are considered as promising leads for anti-tumor drug development.

IT 863924-62-3 863924-64-5

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(inhibitor; tripeptide mimetics inhibit 20S proteasome by covalent bonding to active site threonines in relation to apoptosis induction and anti-tumor drug development)

RN 863924-62-3 HCAPLUS

CN L- α -Asparagine, N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 863924-64-5 HCAPLUS

CN L- α -Asparagine, N-[(phenylmethoxy)carbonyl]-L-leucyl-N-[(1S)-1-formyl-3-methylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 243 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:537072 HCAPLUS

DOCUMENT NUMBER: 143:265082

TITLE: Effect of monophosphoryl lipid A on antibody response

to diphtheria toxin and its subunits

AUTHOR(S): Caglar, Kayhan; Aybay, Cemalettin; Ataoglu, Haluk

CORPORATE SOURCE: Department of Microbiology and Clinical Microbiology,

Faculty of Medicine, Gazi University, Ankara, 06500,

Turk.

SOURCE: APMIS (2005), 113(4), 256-263

CODEN: APMSEL; ISSN: 0903-4641

PUBLISHER: Blackwell Publishing Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB Monophosphoryl lipid A (MPL) was evaluated for its ability to enhance the antibody response to diphtheria toxin and its fragment A and fragment B subunits. BALB/c mice were immunized s.c. with 1 Lf of diphtheria toxoid in the presence of 25 μg of MPL on days 0 and 14. Two weeks after the second immunization, sera were obtained from the mice and analyzed for antibody response to diphtheria toxin and its subunits. A new ELISA method, developed in the authors' laboratory, was used to measure antibody levels against the toxin, fragment A, and fragment B. It was observed that MPL significantly enhanced antibody responses to diphtheria toxin and its subunits. However, there was no statistical difference between anti-A and anti-B responses. The results indicated that MPL seems to be a potential candidate as an adjuvant for future diphtheria vaccine formulation.

IT 143110-73-0, Monophosphoryl lipid A
RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (effect of monophosphoryl lipid A on antibody response to diphtheria
 toxin and its subunits)
RN 143110-73-0 HCAPLUS

CN D-Glucose, 2-deoxy-6-O-[2-deoxy-2-[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]-2[[(3R)-1-oxo-3-[(1-oxohexadecyl)oxy]tetradecyl]amino]- (9CI) (CA INDEX

Absolute stereochemistry. Rotation (+).

NAME)

PAGE 1-A

PAGE 1-B

REFERENCE COUNT:

37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 14 1-3 ibib abs hitstr

L4 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:120874 HCAPLUS

DOCUMENT NUMBER: 140:187354

TITLE: Preparation of PEGylated T20 polypeptide

conjugates as antiviral agents

INVENTOR(S): Bailon, Pascal Sebastian; Won, Chee-Youb

PATENT ASSIGNEE(S):

F. Hoffmann-La Roche AG, Switz.

SOURCE:

PCT Int. Appl., 38 pp.

DOCUMENT TYPE:

CODEN: PIXXD2 Patent

English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PAT	CENT 1	NO.			KIN	D	DATE				ICAT:				D	ATE	
	WO	2004	0131	64		A1	_	2004	0212							2	0030,	716
		W:							AZ,									
			co,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	ΚZ,	LC,	LK,	LR,
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	OM,	PH,
			PL,	PT,	RO,	RU,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,
			UA,	ŪG,	UZ,	VN,	YU,	ZA,	ZM,	ZW								
		RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,
			KG,	ΚZ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,
			FI,	FR,	GB,	GR,	HU,	ΙE,	IT,	LU,	MC,	ΝL,	PT,	RO,	SE,	SI,	SK,	TR,
			BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG
	CA	2493	534			AA		2004	0212	1	CA 2	003-	2493	534		2	0030.	716
	EP	1527	880			A1		2005	0504		EP 2	003-	7661	90		2	0030	716
		R:	AT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	IT,	LI,	LU,	NL,	SE,	MC,	PT,
			ΙE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK	
		2003																
		2004															0030.	721
	NO	2005	0000	66		Α		2005	0422		NO 2	005-	66			2	0050	106
PRIO	RITY	APP	LN.	INFO	.:	į.						002-						
										1	WO 2	003 - 3	EP77	10	1	N 2	0030	716

Pegylated T20 polypeptide compds. are provided. Also provided AΒ are pharmaceutical compns. containing pegylated T20 polypeptide compds., and processes of making and using such compds. and compns. Propionaldehyde-PEG was reacted with T20 to obtain propionaldehyde-PEG-T20 conjugate (I). The IC50 of I was 0.261 μg/mL.

650634-82-5DP, reaction with T20 peptide IT 650634-82-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(preparation of PEGylated T20 polypeptide conjugates as antiviral agents)

RN650634-82-5 HCAPLUS

Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-CN oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC-
$$(CH_2)_3$$
-NH-C- CH_2 -O-CH₂-CH₂-O-Ne

RN 650634-82-5 HCAPLUS

Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-CN oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC-
$$(CH_2)_3$$
-NH-C- CH_2 -O- CH_2 -CH₂-CH₂-O- D

ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER: 2004:64499 USPATFULL TITLE: Pegylated T20 polypeptide

INVENTOR(S): Bailon, Pascal Sebastian, Florham Park, NJ, UNITED

Won, Chee-Youb, Livingston, NJ, UNITED STATES

NUMBER KIND DATE ----- -----A1 PATENT INFORMATION: US 2004049018 20040311 US 2003-623873

A1 APPLICATION INFO .: 20030721 (10)

> NUMBER DATE

US 2002-398195P 20020724 (60) PRIORITY INFORMATION:

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340

KINGSLAND STREET, NUTLEY, NJ, 07110

NUMBER OF CLAIMS: 95 EXEMPLARY CLAIM: 947 LINE COUNT:

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Pegylated T20 polypeptide compounds are provided. Also

provided are pharmaceutical compositions containing pegylated T20 polypeptide compounds, and methods of making and using such

compounds and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 650634-82-5DP, reaction with T20 peptide 650634-82-5P

(preparation of PEGylated T20 polypeptide conjugates as antiviral agents)

650634-82-5 USPATFULL RN

Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-CN oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

RN 650634-82-5 USPATFULL

Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-CN oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

ANSWER 3 OF 3 USPATFULL on STN

2004:25315 USPATFULL ACCESSION NUMBER:

Polyethylene glycol aldehyde's TITLE:

INVENTOR(S): Won, Chee-Youb, Livingston, NJ, UNITED STATES

NUMBER KIND DATE US 2004019157 A1 20040129 PATENT INFORMATION:

APPLICATION INFO.: US 2003-623978 A1 20030721 (10)

NUMBER DATE

PRIORITY INFORMATION: US 2002-398196P 20020724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340

KINGSLAND STREET, NUTLEY, NJ, 07110

NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
LINE COUNT: 974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polyethylene glycol aldehyde compounds are provided. Methods of making and using such compounds, as well as chemical intermediates are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 650634-80-3P 650634-82-5P 650634-83-6P 650634-84-7P

(manufacture of aldehyde derivs. of polyethylene glycol)

RN 650634-80-3 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α -[2-oxo-2-[(4-oxobutyl)amino]ethyl]- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC- (CH₂)₃-NH-C-CH₂ O-CH₂-CH₂ O-CH₂-C-NH-

PAGE 1-B

-- (CH₂)₃ - CHO

RN 650634-82-5 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC-
$$(CH_2)_3$$
-NH-C- CH_2 -O- CH_2 -CH₂-CH₂-O- D n Me

RN 650634-83-6 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α -[2-[(4,4-diethoxybutyl)amino]-2-oxoethyl]- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

650634-84-7 USPATFULL RN

CN Poly(oxy-1,2-ethanediyl), α -[2-oxo-2-[(3-oxopropyl)amino]ethyl]- ω -[2-oxo-2-[(3-oxopropyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A

OHC-
$$CH_2$$
- CH_2 - NH - C - CH_2

PAGE 1-B

— cн₂- сно

=> d his

(FILE 'HOME' ENTERED AT 14:38:01 ON 02 DEC 2005)

FILE 'REGISTRY' ENTERED AT 14:38:16 ON 02 DEC 2005

L1STRUCTURE UPLOADED

391 S L1 FULL L2

FILE 'HCAPLUS, USPATFULL' ENTERED AT 14:39:42 ON 02 DEC 2005

243 L2 L3

3 L3 AND T20 L44 L3 AND T1249 L5 2 L4 AND L5 L6

=> d 15 1-4 ibib abs hitstr

ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER:

2004:120875 HCAPLUS

DOCUMENT NUMBER:

140:187355

TITLE:

Preparation of PEGylated T1249 polypeptide

conjugates as antiviral agents

INVENTOR(S):

Bailon, Pascal Sebastian; Won, Chee-Youb F. Hoffmann-La Roche AG, Switz.

PATENT ASSIGNEE(S):

SOURCE:

PCT Int. Appl., 61 pp.

DOCUMENT TYPE:

CODEN: PIXXD2

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-				
WO 2004013165	A1	20040212	WO 2003-EP7711	20030716

AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG CA 2492954 20040212 CA 2003-2492954 AA 20030716 EP 1546193 EP 2003-766191 A1 20050629 20030716 AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK US 2004171542 Α1 20040902 US 2003-625103 20030722 NO 2005000067 Α 20050422 NO 2005-67 20050106 PRIORITY APPLN. INFO.: US 2002-398190P Р 20020724 US 2003-439213P Ρ 20030110 WO 2003-EP7711 W 20030716

AB Pegylated T1249 polypeptide compds. are provided. Also provided are pharmaceutical compns. containing pegylated T1249 polypeptide compds., and processes of making. Further provided is the use of pharmaceutical composition comprising, in admixt. with a pharmaceutically acceptable excipient, a PEGylated T1249 polypeptide conjugate, for the preparation of a medicament for the inhibition of HIV infection. Propionaldehyde-PEG was reacted with T1249 to obtain propionaldehyde-PEG-T1249 conjugate. Antiviral efficacy of the conjugate was shown in rats.

IT 650634-82-5DP, reaction with T1249 650634-82-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

RN 650634-82-5 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC-
$$(CH_2)_3$$
-NH-C- CH_2 -O- CH_2 -CH2- CH_2 -O- D - D

RN 650634-82-5 HCAPLUS

CN Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC- (CH₂)₃-NH-C-CH₂-O-
$$\begin{bmatrix} CH_2-CH_2-O \\ D \end{bmatrix}$$
 Me

L5 ANSWER 2 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:221771 USPATFULL

TITLE:

Pegylated T1249 polypeptide

INVENTOR(S): Bailon, Pascal Sebastian, Florham Park, NJ, UNITED

STATES

Won, Chee-Youb, Livingston, NJ, UNITED STATES

NUMBER KIND DATE _____

US 2004171542 A1 PATENT INFORMATION: 20040902

APPLICATION INFO.: US 2003-625103 A1 20030722 (10)

> NUMBER DATE

US 2003-439213P 20030110 (60) PRIORITY INFORMATION:

US 2002-398190P 20020724 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340 LEGAL REPRESENTATIVE:

KINGSLAND STREET, NUTLEY, NJ, 07110

NUMBER OF CLAIMS: 149

EXEMPLARY CLAIM:

7 Drawing Page(s) NUMBER OF DRAWINGS:

LINE COUNT: 1472

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

Pegylated T1249 polypeptide compounds are provided. Also provided are pharmaceutical compositions containing pegylated T1249 polypeptide compounds, and methods of making. Further

provided are methods of inhibiting HIV infection using such compounds

and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

650634-82-5DP, reaction with T1249 650634-82-5P

(preparation of PEGylated T1249 polypeptide conjugates as antiviral agents)

RN 650634-82-5 USPATFULL

Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-CN oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC-
$$(CH_2)_3$$
-NH-C- CH_2 -O- CH_2 -CH2-O- D n Me

650634-82-5 USPATFULL RN

Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-CN oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC-
$$(CH_2)_3$$
-NH-C- CH_2 -O- CH_2 -CH2- CH_2 -O- D

ANSWER 3 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:64499 USPATFULL TITLE: Pegylated T20 polypeptide

INVENTOR(S): Bailon, Pascal Sebastian, Florham Park, NJ, UNITED

Won, Chee-Youb, Livingston, NJ, UNITED STATES

NUMBER KIND DATE US 2004049018 A1 PATENT INFORMATION: 20040311 APPLICATION INFO.: US 2003-623873 A1 20030721 (10) NUMBER DATE

PRIORITY INFORMATION: US 2002-398195P 20020724 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340

KINGSLAND STREET, NUTLEY, NJ, 07110

NUMBER OF CLAIMS: 95 EXEMPLARY CLAIM: 1 LINE COUNT: 947

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pegylated T20 polypeptide compounds are provided. Also provided are pharmaceutical compositions containing pegylated T20 polypeptide compounds, and methods of making and using such compounds and compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 650634-82-5DP, reaction with T20 peptide 650634-82-5P

(preparation of PEGylated T20 polypeptide conjugates as antiviral agents)

RN 650634-82-5 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC-
$$(CH_2)_3$$
-NH-C- CH_2 -O- CH_2 -CH2-O- D n Me

RN 650634-82-5 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

L5 ANSWER 4 OF 4 USPATFULL on STN

ACCESSION NUMBER: 2004:25315 USPATFULL

TITLE: Polyethylene glycol aldehydes

INVENTOR(S): Won, Chee-Youb, Livingston, NJ, UNITED STATES

NUMBER DATE

PRIORITY INFORMATION: US 2002-398196P 20020724 (60)

DOCUMENT TYPE: Utility FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HOFFMANN-LA ROCHE INC., PATENT LAW DEPARTMENT, 340

KINGSLAND STREET, NUTLEY, NJ, 07110

NUMBER OF CLAIMS: 86
EXEMPLARY CLAIM: 1
LINE COUNT: 974

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polyethylene glycol aldehyde compounds are provided. Methods of making and using such compounds, as well as chemical intermediates are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 650634-80-3P 650634-82-5P 650634-83-6P

650634-84-7P

(manufacture of aldehyde derivs. of polyethylene glycol)

RN 650634-80-3 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α -[2-oxo-2-[(4-oxobutyl)amino]ethyl]- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-B

- (CH₂)₃-CHO

RN 650634-82-5 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α -methyl- ω -[2-oxo-2-[(4-oxobutyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC-
$$(CH_2)_3$$
-NH-C- CH_2 -O- CH_2 -CH₂-O- CH_2 -O- C

RN 650634-83-6 USPATFULL

CN Poly(oxy-1,2-ethanediy1), α -[2-[(4,4-diethoxybuty1)amino]-2-oxoethy1]- ω -[2-oxo-2-[(4-oxobuty1)amino]ethoxy]- (9CI) (CA INDEX NAME)

OHC- (CH₂)₃-NH-C-CH₂-O-
$$\begin{bmatrix} CH_2-CH_2-O \\ \end{bmatrix}_n$$
 CH₂-C-NH-

PAGE 1-B

RN 650634-84-7 USPATFULL

CN Poly(oxy-1,2-ethanediyl), α -[2-oxo-2-[(3-oxopropyl)amino]ethyl]- ω -[2-oxo-2-[(3-oxopropyl)amino]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A

$$\text{OHC-} \ \text{CH}_2 - \text{CH}_2 - \text{NH-} \ \text{C-} \ \text{CH}_2 - \text{CH}_$$

PAGE 1-B

— cн₂— сно

Structure attributes must be viewed using STN Express query preparation.

L2 391 SEA FILE=REGISTRY SSS FUL L1

L3 243 SEA L2

L4 3 SEA L3 AND T20 L5 4 SEA L3 AND T1249 L6 2 SEA L4 AND L5

=> d his full

L3

(FILE 'HOME' ENTERED AT 14:38:01 ON 02 DEC 2005)

FILE 'REGISTRY' ENTERED AT 14:38:16 ON 02 DEC 2005

L1 STRUCTURE UPLOADED

DIS

L2 391 SEA SSS FUL L1

FILE 'HCAPLUS, USPATFULL' ENTERED AT 14:39:42 ON 02 DEC 2005

243 SEA ABB=ON PLU=ON L2

L4 3 SEA ABB=ON PLU=ON L3 AND T20 L5 4 SEA ABB=ON PLU=ON L3 AND T1249 L6 2 SEA ABB=ON PLU=ON L4 AND L5

D L3 1-3 IBIB ABS HITSTR

D L4 1-3 IBIB ABS HITSTR

D L5 1-4 IBIB ABS HITSTR

D QUE STAT

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8 DICTIONARY FILE UPDATES: 30 NOV 2005 HIGHEST RN 869059-01-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

* The CA roles and document type information have been removed from the IDE default display format and the ED field has been added, effective March 20, 2005. A new display format, IDERL, is now available and contains the CA role and document type information.

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Dec 2005 VOL 143 ISS 24 FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 1 Dec 2005 (20051201/PD)

FILE LAST UPDATED: 1 Dec 2005 (20051201/ED)

HIGHEST GRANTED PATENT NUMBER: US6971121

HIGHEST APPLICATION PUBLICATION NUMBER: US2005268363

CA INDEXING IS CURRENT THROUGH 1 Dec 2005 (20051201/UPCA)


ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 1 Dec 2005 (20051201/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2005

>>>	USPAT2 is now available. USPATFULL contains full text of the	<<<
>>>	original, i.e., the earliest published granted patents or	<<<
>>>	applications. USPAT2 contains full text of the latest US	<<<
>>>	publications, starting in 2001, for the inventions covered in	<<<
>>>	USPATFULL. A USPATFULL record contains not only the original	<<<
>>>	published document but also a list of any subsequent	<<<
>>>	publications. The publication number, patent kind code, and	<<<
>>>	publication date for all the US publications for an invention	<<<
>>>	are displayed in the PI (Patent Information) field of USPATFULL	<<<
>>>	records and may be searched in standard search fields, e.g., /PN,	<<<
>>>	/PK, etc.	<<<
>>>	USPATFULL and USPAT2 can be accessed and searched together	<<<
>>>	through the new cluster USPATALL. Type FILE USPATALL to	<<<
>>>	enter this cluster.	<<<
>>>		<<<
>>>	Use USPATALL when searching terms such as patent assignees,	<<<
>>>	classifications, or claims, that may potentially change from	<<<
>>>	the earliest to the latest publication.	<<<

This file contains CAS Registry Numbers for easy and accurate substance identification.



chain nodes:

1 2 3 4 5 6 7 8 9 10 11

chain bonds : 1-2 2-3 3-4 4-5 5-6 5-7 7-8 8-9 9-10 9-11

exact/norm bonds :

2-3 3-4 5-6 5-7 7-8 9-10 exact bonds :

1-2 4-5 8-9 9-11

Match level:

1:CLASS2:CLASS3:CLASS4:CLASS5:CLASS6:CLASS7:CLASS8:CLASS9:CLASS 10:CLASS11:CLASS